Home Cart Sign in  
Chemical Structure| 53-84-9 Chemical Structure| 53-84-9
Chemical Structure| 53-84-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NAD+ is an important coenzyme that plays a critical role in cellular metabolism and energy production. NAD+ is mainly used in research on metabolism, aging, and cellular energetics.

Synonyms: β-DPN; β-NAD; BRN3584133

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Kei Takahash ; Emiko Sato ; Seiko Yamakoshi ; Mizuki Ogane ; Akiyo Sekimoto ; Takamasa Ishikawa , et al.

Abstract: Podocytes are key components of the glomerular filtration barrier, and their injury leads to proteinuria, chronic kidney disease (CKD), and nephrotic syndrome. Effective treatments for these conditions are not well established, and prevention of podocyte injury is a crucial challenge. Nicotinamide (NAM), a form of vitamin B3, has been reported to exert beneficial effects in various renal disease models due to its antioxidant and anti-inflammatory properties and its ability to replenish nicotinamide adenine dinucleotide (NAD+ ). However, its impact on adriamycin (ADR)-induced nephropathy, a model of nephrotic syndrome caused by podocyte injury, remains unclear. We investigated the effects of NAM administration in a mouse model of ADR nephropathy. BALB/c mice were intravenously administered ADR to induce nephropathy. In the NAM-treated group, mice received 0.6% NAM in drinking water ad libitum starting 7 days before ADR administration. After 14 days, NAM treatment decreased albuminuria, glomerular sclerosis, and podocyte injury, and reduced inflammation and oxidative stress markers in the kidneys. NAM and NAD+ levels were decreased in ADR-treated kidneys, and the expression of the NAD+ -consuming enzymes SIRT1 and poly(ADP-ribose) polymerase 1 (PARP-1) was decreased and increased, respectively. Nicotinamide N-methyltransferase expression was increased. NAM canceled these abnormalities. In cultured rat podocytes, NAD+ alleviated ADR-induced cytotoxicity, apoptosis, and inflammation. These findings suggest that NAM prevents ADR nephropathy and podocyte injury, likely through NAD+ replenishment.

Purchased from AmBeed: ; ; ;

Alternative Products

Product Details of NAD+

CAS No. :53-84-9
Formula : C21H27N7O14P2
M.W : 663.43
SMILES Code : O[C@H]1[C@H](N2C3=C(N=C2)C(N)=NC=N3)O[C@@H]([C@H]1O)COP(OP(OC[C@H]4O[C@H]([C@@H]([C@@H]4O)O)[N+]5=CC=CC(C(N)=O)=C5)([O-])=O)(O)=O
Synonyms :
β-DPN; β-NAD; BRN3584133
MDL No. :MFCD00036253

Safety of NAD+

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H371
Precautionary Statements:P260-P264-P270-P308+P311-P405-P501

Application In Synthesis of NAD+

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 53-84-9 ]

[ 53-84-9 ] Synthesis Path-Downstream   1~1

  • 1
  • [ 53-84-9 ]
  • [ 273-34-7 ]
  • C20H25N9O13P2 [ No CAS ]
  • C20H25N9O13P2 [ No CAS ]
 

Historical Records

Categories